1) Leadership Transition and Strategy Execution - Vitor Roque has been appointed as CFO after serving as Interim CFO, reflecting confidence in internal talent. - The leadership team emphasizes executing the "New BD" strategy, focusing on commercial excellence, innovation, and operational delivery. - The company is committed to enhancing capital allocation strategies while driving shareholder value.

2) Financial Performance and Segment Results - Q2 revenue reached $4.7 billion, up 2.6% YoY, with over 90% of the portfolio achieving mid-single-digit growth. - Adjusted operating margin was 24.2%, and adjusted EPS was $2.90, reflecting strong operational execution. - Key growth platforms such as biologic drug delivery, Advanced Patient Monitoring, and PureWick saw double-digit growth, while Alaris, vaccines, and China presented headwinds.

3) Operational Challenges and Headwinds - Alaris, vaccines, and market dynamics in China are expected to continue impacting revenue, contributing to a 200 basis point headwind in 2027. - The company is managing these challenges, with Alaris showing share gains, but overall performance is affected by these segments. - An FDA warning letter regarding the El Paso facility has led to a temporary ship hold on ChloraPrep and PurPrep products, with no patient safety signals reported.

4) Innovation and Product Development - BD is expanding its innovation pipeline, with a focus on high-growth areas such as Connected Care and chronic disease treatments. - The company has launched several new products, including the EnCor EnCompass Biopsy System and HemoSphere Stream Module, enhancing its market position. - BD Excellence is being applied to R&D, reducing time to launch by over 10 months on average for development programs.

5) Guidance and Outlook - BD has raised its full-year adjusted EPS guidance to a range of $12.52 to $12.72, reflecting confidence in continued performance. - Revenue growth is expected to remain in the low single digits for the full year, with the second half anticipated to mirror the first half. - The company is focused on disciplined capital allocation, prioritizing share repurchases while maintaining a strong balance sheet.

Bottom line: BD's solid Q2 performance, driven by strategic execution and innovation, positions the company well for future growth despite facing headwinds in specific segments. The leadership transition and commitment to operational excellence enhance confidence in delivering long-term shareholder value.